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Sir, Treatment trials for diabetic macular oedema
In a recent review in Eye, Amoaku et al 1 identify the need for a therapy for centre-involved diabetic macular oedema (DMO) that (i) dries the retina and improves visual acuity for a significant period, (ii) reduces adverse events, treatment burden, and costs, and (iii) is well-tolerated by patients. 1 They then make the case for an intravitreal injection regime that includes both steroids and antagonists against vascular endothelial growth factor (VEGF). The rationale was based on myriad putative mechanisms of drug action together with the results of randomised controlled trials of monotherapies. Combining a steroid with an anti-VEGF agent was said to hold promise of improved anatomical and functional outcomes together with a reduction in the (otherwise monthly) regularity of injections. This is despite the fact that previous clinical trials have shown no such adjunctive benefit. [2] [3] [4] [5] In the experience of many vitreoretinal surgeons, a permanent cure for DMO can often be achieved by 'one-off' vitrectomy and removal of the internal limiting membrane (ILM). A neuroprotective and sustentacular role for reparative intraretinal gliosis has been invoked. Recently, the superiority of ILM peeling over other therapies for DMO has been suggested by a non-randomised study. 6 If future trials of intravitreal therapies for DMO are contemplated, one arm of the study should comprise vitrectomy and ILM peeling. The review is an excellent summary of all literature on this interesting topic; nevertheless, one of the largest surgical case series is missing. This paper was published by Panozzo and Mercanti in 2007, and describes 24 highly myopic eyes with myopic traction maculopathy (MTM) successfully treated by pars plana vitrectomy with epiretinal and ILM peeling. 2 Differently from other published series, the authors achieved complete retinal settling in 23 of 24 eyes without any gas tamponade in a mean time of 4.4 months.
This series is not only one of the largest series ever published, but it is also in my opinion to be mentioned because the surgical success obtained by simple peeling without tamponade strongly supports the hypothesis that MTM is mainly due to diffuse traction from epiretinal forces and from the non-elastic ILM stretched by the myopic bulb elongation and staphyloma. Sir, Combination of peripheral laser photocoagulation with intravitreal bevacizumab in naïve eyes with macular edema secondary to CRVO: prospective randomized study Increased vascular endothelial growth factor (VEGF) production has been reported in central retinal vein occlusion (CRVO), which could be due to peripheral retinal ischemia. 1 Panretinal laser photocoagulation (PLP) in peripheral retina has been shown to reduce the VEGF production. 2 Here, we report 1-year results of a prospective randomized single-masked trial comparing 1.25 mg intravitreal bevacizumab pro-re-nata (PRN) monotherapy and PRN therapy in combination with PLP at 1 month in treatment of naive eyes with macular edema (ME) secondary to CRVO.
Naive eyes with center-involving ME secondary to CRVO of o9 months duration, minimum central subfield thickness (CST) of 250 μm on spectral domain optical coherence tomography, and best-corrected visual acuity of 24-73 letters were included. Subjects were randomized to either monotherapy or combination group. Through month 12, subjects were evaluated monthly and treated with intravitreal injections on a PRN basis as per predefined retreatment criteria. Seven field fluorescein angiography and electroretinography (ISCEV standards) were performed at baseline, month 6 and month 12. Wilcoxon signed-rank test was performed to evaluate changes in visual acuity and CST.
Twenty-two eyes of 21 consecutive subjects were enrolled. Baseline characteristics of both groups are shown as Table 1 . Mean change in visual acuity in monotherapy and combination group at the last visit from baseline was 24.61 (P = 0.001) and 25.49 (P = 0.001) letters, respectively (P = 0.32). Mean decrease in CST in monotherapy and combination group at the last visit from baseline was 515 ± 202 (P = 0.0002) and 642 ± 224 (P = 0.0003) microns, respectively (P = 0.3) (Figure 1 ). Mean number of injections in monotherapy and combination group was 6.0 ± 3.17 and 6.7 ± 3.59, respectively (P = 0.33). There was no significant difference in b/a ratio on ERG between two groups.
Spaide 3 reported outcome of 10 eyes, which underwent peripheral laser photocoagulation during the treatment with ranibizumab. He reported no difference in the number of injections (3.4 vs 3.1) 6 months before and after peripheral laser photocoagulation. Similar to our results, RETAIN and RELATE trials also reported no benefits of PLP. 4, 5 In conclusion, early PLP in eyes with CRVO neither shows additional benefits on functional outcome nor to reduce the number of injections during the 1-year follow-up. 
